Safety concerns raised for ArQule, Daiichi Sankyo's cancer drug
This article was originally published in Scrip
Executive Summary
US biotech company ArQule said a monitoring committee raised concerns about dosing level and the safety of a liver cancer therapy the drug maker is testing with partner Daiichi Sankyo.